Drug Database
TK

TK-129 (TK 129 / TK129)

✓ Approved

Foshan Rexiu Biotechnology · LRP1

What is TK-129?

TK-129 is a therapeutic agent developed by Foshan Rexiu Biotechnology. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesTK 129, TK129
CompanyFoshan Rexiu Biotechnology
Molecular TargetLRP1
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Foshan Rexiu Biotechnology

Mechanism of Action

Molecular Targets

TK-129 acts on 1 molecular target:

LRP1LDL receptor related protein 1 (LRP1A, A2MR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

TK-129 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Rectosigmoid cancer✓ Approved

Related Research Articles

PubMedTranslational lung cancer research2026-10-14

Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy.

Quan Xiru X, Xuzhang Wendi W, Shen Shengping S, Yang Ying Y et al.

Immunotherapy, either as a monotherapy or in combination with chemotherapy, has become the standard first-line treatment for advanced lung adenocarcinoma (LUAD) without driver mutations. Although TP53 is frequently mutated in LUAD, the clinical significance of different TP53 mutation subtypes in the setting of first-line immunotherapy remains poorly defined. This study aimed to evaluate the association between TP53 mutation subtypes and treatment outcomes in patients with locally advanced or metastatic LUAD receiving first-line immunotherapy or chemo-immunotherapy. A total of 129 locally advanced or metastatic LUAD patients with TP53 mutations receiving first-line immunotherapy or chemo-immunotherapy between January 2018 and November 2022 at Shanghai Chest Hospital were retrospectively analyzed. TP53 mutation status was confirmed by next-generation sequencing (NGS). Kaplan-Meier analysis and Cox proportional hazards model were employed to analyze the effect of TP53 mutation subtypes on treatment outcomes. TP53 mutations were categorized into four groups: missense, nonsense, frameshift, and others. Missense mutations were the most frequent subtype (78/129, 60.5%), followed by frameshift (23/129, 17.8%), nonsense (18/129, 14.0%), and others (10/129, 7.8%). Patients with TP53 frameshift mutations exhibited worse progression-free survival (PFS) (median PFS, 6.0 vs. 13.5 months; P=0.002) and overall survival (OS) (median OS, 13.3 vs. 39.9 months; P<0.001) than those with non-frameshift mutations. A significantly higher proportion of patients in the frameshift group experienced progressive disease (PD) as their best overall response than in the non-frameshift group (30.4% vs. 7.6%, P=0.006). In multivariate analysis, TP53 frameshift mutations remained independently associated with inferior PFS [hazard ratio (HR) =2.229, 95% confidence interval (CI): 1.337-3.715, P=0.002] and OS (HR =3.278, 95% CI: 1.730-6.210, P<0.001). In this retrospective cohort, TP53 frameshift mutations were associated with poorer survival in patients with advanced LUAD receiving first-line immunotherapy or chemo-immunotherapy, suggesting distinct prognostic implications across TP53 mutation subtypes.

PMID 42870812
Read full article →
PubMedJournal of hazardous materials2026-10-14

Mechanisms of biochar derived from chicken manure or rice straw that effectively immobilizes cadmium do not apply to sewage-sludge biochar.

Huang Fei F, Liang Kai-Ming KM, Li Jun-Chun JC, Hu Zhi-Wen ZW et al.

In order to explore immobilization characteristic and its possible mechanism of various feedstocks-based biochars, deriving from chicken manure (CMB), rice straw (RSB) and sewage sludge (SSB), the effect of three biochars on speciation transformation of Cd in soil was compared, and soil properties, microbial community diversity were also examined. The treatment of CMB and RSB reduced significantly the content of acid-extractable Cd by 53.62% and 41.18%, respectively, but this available fraction was increased by 23.44% after SSB treatment. Simultaneously, CMB and RSB treatment significantly increased the soil pH, CEC, TOC, AN, AP, TK, microbial biomass carbon, dehydrogenase, phosphatase, catalase and urease enzyme activity, while SSB treatment slightly increased AP and TK content, only decreased urease enzyme activity. Lower bacterial alpha diversity was observed at the initial sampling of day 0, whereas treatment differences in bacterial Shannon diversity were not significant at day 225, it suggested that their effects on microbial alpha diversity were dependent on sampling stage and microbial kingdom. Partial least squares modelling (PLS-PM) speculated that CMB and RSB treatment decreased available Cd through direct effect of biochar and indirect effect of soil, whereas SSB treatment elevated available metal by indirect effect. This increase might be due to the decrease of urease activity indirectly affected by SSB, thus decelerating Cd precipitation and enhancing available Cd. These results deepen our understanding on the degree of immobilization and underlying mechanisms for Cd in soil that is critical for evaluating the application of effective biochar treatments.

PMID 42874207
Read full article →
PubMedCancer treatment reviews2026-10-14

Artificial intelligence-enabled drug discovery: A growing but largely early-stage clinical pipeline.

Haque Waqas W, Sai-Palm Kareena K, Rana Iemaan I, Esposito Alessandra A et al.

Artificial intelligence (AI) is increasingly integrated into pharmaceutical discovery, yet the extent to which AI-enabled assets have translated into clinical-stage programs remains incompletely characterized. We performed a cross-sectional descriptive analysis of therapeutic assets discovered or developed using AI approaches that had entered at least one interventional human clinical trial through March 1, 2026. We identified 129 AI-enabled therapeutic assets across 69 companies. Oncology was the dominant therapeutic area (74 assets, 57.3%), and small molecules accounted for the majority of the pipeline (103 assets, 79.8%). Among these assets, 72 (55.8%) had completed Phase 1 and 24 (18.9%) had completed Phase 2; only five had entered or completed Phase 3. The observed probability of success was 77.8% for Phase 1 and 19.5% for Phase 2. Forty-eight assets (37.2%) were classified as targeting a novel biological target. Among companies with available data, the median time from founding to Phase 1 entry was 6.5 years (IQR 4.0-9.2), median total funding raised was $186.7 million (IQR $48.1-$595.0 million), and the median employee count at clinical entry was 73 (IQR 32-129), with a median operational intensity of $2.72 million per employee. AI-enabled therapeutics are entering clinical testing at increasing scale, but most programs remain early in development, with few having advanced beyond Phase 2. This dataset provides a baseline for future evaluation of whether AI-enabled discovery ultimately improves regulatory approval rates and clinical outcomes.

PMID 42874241
Read full article →
PubMedNature communications2026-10-14

Widespread declines of formerly common species reshape local assemblages over time.

Xu Weiqiang W, Gao Junfeng J, Su Qiang Q, Lv Xiaorui X et al.

Despite dramatic human-driven changes across ecosystems, local-scale aggregate biodiversity metrics are often surprisingly stable, even as communities experience substantial reorganization of species identities and relative abundances. While rare species are often thought to be more vulnerable to these changes, emerging evidence suggests that common species may experience disproportionately greater declines. To evaluate these alternatives, we synthesize population trends for species initially rare or common across assemblages from 4748 sites within 129 studies spanning terrestrial, freshwater, and marine ecosystems. We quantify how population trends relate to initial abundances using hierarchical Bayesian models that account for regression to the mean and include realm, taxon, and environmental covariates. We find consistently stronger declines among formerly common species in marine and terrestrial assemblages, while freshwater assemblages show no clear directional pattern. Rare species present at the start also decline, but less so than common species, while colonists that were not present at the start of the time series compensate for losses within the rarest abundance category. Climate change and anthropogenic drivers modulate these trends, with increasing temperature and non-climatic human pressures attenuating losses of initially common species, particularly in marine systems. Overall, we find widespread declines in common species through time, with potential functional consequences.

PMID 42869934
Read full article →
PubMedSpine2026-10-14

Surgical and Radiographic Outcomes in Cervical Deformity Patients with High T1 Slope and High C2 Slope (HTHC) Versus Low T1 Slope and High C2 Slope (LTHC): Distinct Phenotypes of Cervical-Only versus Global Spinal Deformity.

Kucherina Alexander A, Norris Zoe Z, Balouch Eaman E, Lafage Renaud R et al.

Retrospective analysis of a prospective multicenter operative cervical deformity (CD) database. To determine whether T1 slope (T1S) and C2 slope (C2S) together identify distinct CD phenotypes: cervical-only versus global sagittal deformity, and to compare surgical invasiveness, radiographic correction, and patient-reported outcomes. T1S and C2S mark cervical malalignment, and elevated T1S has been linked to global sagittal malalignment. Combining them may distinguish CD-only from global deformity on cervical imaging alone. Operative CD patients with ≥2 years follow-up and preoperative C2S >30° were stratified by T1S into low T1S-high C2S (LTHC; ≤30°) and high T1S-high C2S (HTHC; >30°). Multivariable regression assessed group effect on 2-year NDI change, adjusted for age, sex, baseline NDI, and posterior levels fused. NDI MCID was set a priori at ≥7 points per the ISSG threshold. Ninety-two patients met criteria (31 LTHC, 61 HTHC). HTHC patients were older (64.7 vs. 60.0 years; P=0.035) with higher Charlson index (P=0.022). Preoperatively, HTHC had greater thoracic kyphosis, TPA, cSVA, PI-LL mismatch, and C7 SVA (all P≤0.010). HTHC underwent more extensive surgery: more posterior levels fused (10.3 vs. 6.7), more circumferential fusions (66.7% vs. 38.7%), and more caudal LIV (T7 vs. T3) (all P<0.05). At 2 years, HTHC retained higher TK and cSVA despite greater absolute correction. Baseline NDI was similar (P=0.906), but 2-year NDI improvement was smaller in HTHC (-6.2 vs. -14.6 points; P=0.013), and fewer achieved MCID (45.9% vs. 71.0%; P=0.022). HTHC remained an independent predictor of smaller improvement (β=+7.4; P=0.020). Reoperation, DJK, and complication rates did not differ. Among CD patients with elevated C2S, additional elevated T1S identifies a global-deformity phenotype requiring more invasive correction and showing smaller 2-year patient-reported improvement despite comparable complications. T1S and C2S, measurable on cervical imaging alone, screen for which CD patients warrant full-spine imaging. III (retrospective analysis of prospectively collected multicenter data).

PMID 42873977
Read full article →
PubMedMidwifery2026-10-14

Postnatal depressive symptoms and associated factors among parents of newborns: a cross-sectional study in tropical Sanya, China.

Ye Xiuxia X, Huang Daosheng D, Zhan Enling E, Yan Shuting S et al.

To determine the prevalence of postnatal depressive symptoms and associated factors among parents of newborns in Sanya, a tropical city in China. A hospital-based cross-sectional survey with prospective data collection. Shanghai Children's Medical Center, Hainan Branch, Sanya, China, between February and March 2025. 263 parents of newborns aged 0-4 weeks (134 fathers, 129 mothers) recruited by consecutive sampling. Each parent consented individually, with data treated independently. Exposures were parental gender, perceived social support, life satisfaction, quality of life, and sociodemographic factors. The outcome was elevated depressive symptoms, defined as an Edinburgh Postnatal Depression Scale score of 13 or more. Participants self-completed the Multidimensional Scale of Perceived Social Support (MSPSS), Satisfaction with Life Scale (SWLS), and WHO Quality of Life-BREF (WHOQOL-BREF) through a secure online platform. Overall, 58 of 263 parents (22.1%) had elevated postnatal depressive symptoms, a higher prevalence than the global average. After adjustment, mothers had higher odds than fathers (adjusted odds ratio [aOR] = 3.14, 95% confidence interval [CI]: 1.41-6.97), and each one-point increase in the WHOQOL-BREF psychological domain score was associated with a 61% reduction in the odds of elevated symptoms (aOR = 0.39, 95% CI: 0.15-0.99). Postnatal depressive symptoms are common among parents in this tropical, ethnically diverse setting, with maternal vulnerability particularly pronounced. The findings support routine screening of both mothers and fathers, targeted outreach for migrant and low-income families, and integration of resilience-building into perinatal care in tropical settings.

PMID 42874463
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about TK-129